Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma.
Yusuke MatobaDominique T ZarrellaVenkatesh PooladandaMaryam Azimi MohammadabadiEugene KimShaan KumarMengyao XuXingping QinLauren J RayKyle M DevinsRaj KumarArtem KononenkoEric EisenhauerIrva E VeillardWataru YamagamiSarah J HillKristopher A SarosiekOladapo O YekuDavid R SpriggsBo R RuedaPublished in: British journal of cancer (2024)
These findings suggest inhibiting Gal3 may benefit USC patients.